Bobak Azamian, Tarsus CEO
Tarsus to raise $75.6M for repurposed dog drug that's headed to FDA after eye drop's PhIII win
Tarsus Pharmaceuticals will ship its eye drop off to the FDA before year’s end in the hopes of securing the first regulatory nod for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
